By IDSE News Staff
The FDA approved the live-attenuated dengue tetravalent vaccine (Dengvaxia, Sanofi Pasteur), the first vaccine for preventing dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in children 9 through 16 years of age with laboratory-confirmed previous dengue infection and who live in endemic areas.
The dengue tetravalent vaccine is the first and only vaccine approved for protection against dengue in endemic areas of the United States. Although dengue cases are